AgNovos Healthcare Enters Exclusive Option Agreement with Asahi Kasei Pharma

AgNovos Healthcare is pleased to announce an exclusive option agreement with Asahi Kasei Pharma Corporation. To learn more about this partnership and the commercialization of AgNovos’ lead product, AGN1 LOEP Hip Kit, in Japan, click here to see the formal announcement.

Read more

AgNovos Healthcare to Participate in Fragility Fracture Network Congress

AgNovos Healthcare will participate in this year’s virtual Fragility Fracture Network Congress from September 28-30th. AgNovos will host a virtual booth and sponsor a symposium to share the latest data related to its CE-marked OSSURE LOEP kit and its use to form bone in the proximal femurs of people at risk of hip fragility fractures. Click here to learn more and register for the congress.

Read more

AgNovos Healthcare to Participate in Swiss Association Against Osteoporosis (SVGO/ASCO) Continuing Education Day

AgNovos will participate in this year’s Swiss Association Against Osteoporosis continuing education day on metabolic bone disease on September 23 in Bern, Switzerland. AgNovos will share data related to its CE-marked OSSURE LOEP kit and its use to form bone in the proximal femurs of people at risk of hip fragility fractures. Click here to learn more and register for the congress.

Read more

AgNovos Healthcare to Participate in British Orthopaedic Association Congress

AgNovos Healthcare will participate in this year’s British Orthopaedic Association Congress from September 21-24 in Aberdeen, Scotland. AgNovos will host a booth and sponsor an educational symposium (September 21, 12:55pm BST). The symposium will focus on the status of secondary hip fragility fracture risk and feature Prof Benjamin Ollivere and Prof Andrew Duckworth. Click here to learn more and register for the congress.

Read more

Archive

Category